[1]李迪婧,胡良安,张 丹.慢性阻塞性肺疾病合并肺曲霉病危险因素的Meta分析[J].医学信息,2020,33(13):69-75,79.[doi:10.3969/j.issn.1006-1959.2020.13.019]
 LI Di-jing,HU Liang-an,ZHANG Dan.Meta-analysis of Risk Factors for Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Aspergillosis[J].Medical Information,2020,33(13):69-75,79.[doi:10.3969/j.issn.1006-1959.2020.13.019]
点击复制

慢性阻塞性肺疾病合并肺曲霉病危险因素的Meta分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年13期
页码:
69-75,79
栏目:
论著
出版日期:
2020-07-01

文章信息/Info

Title:
Meta-analysis of Risk Factors for Chronic Obstructive Pulmonary Disease Complicated with Pulmonary Aspergillosis
文章编号:
1006-1959(2020)13-0069-08
作者:
李迪婧胡良安张 丹
(重庆医科大学附属第一医院呼吸与危重症医学科,重庆 400016)
Author(s):
LI Di-jingHU Liang-anZHANG Dan
(Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
关键词:
肺疾病慢性阻塞性肺曲霉病危险因素
Keywords:
Pulmonary diseaseChronic obstructivePulmonary aspergillosisRisk factors
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2020.13.019
文献标志码:
A
摘要:
目的 探讨慢性阻塞性肺疾病患者发生肺曲霉病的危险因素,为慢阻肺患者制定临床管理策略提供依据。方法 检索中文数据库中国知网(CNKI)、维普(VIP)、万方,英文数据库PubMed、Embase、Cochrane Library 2000年6月1日~2019年6月1日公开发表的慢性阻塞性肺疾病发生肺曲霉病相关因素的研究文献,参照Wells等制定的文献质量评价量表(NOS)对文献进行质量评价,利用Revman5.3、Stata15软件进行Meta分析。结果 共纳入文献25篇,均为病例对照研究,其中英文8篇,中文17篇,病例组995例、对照组3117例。Meta分析显示:吸烟史、住院天数、入住ICU、机械通气、侵入性操作、使用糖皮质激素、使用抗生素、GOLD Ⅲ~Ⅳ级、糖尿病、真菌定植或既往感染、低蛋白血症、APACHⅡ评分高是慢性阻塞性肺疾病患者发生肺曲霉病的危险因素。结论 慢性阻塞性肺疾病患者发生肺曲霉病是多种危险因素共同作用的结果,与患者的治疗方式、既往病史、合并症等密切相关,但由于客观因素限制,部分结果可能仍存在偏倚,还需进一步研究验证。
Abstract:
Objective To systematically evaluate the risk factors of pulmonary aspergillosis in patients with chronic obstructive pulmonary disease (COPD) and provide the basis for clinical management strategies of COPD patients.Methods SearchingChinese databases(CNKI,VIP and Wangfang) and English databases(PubMed,Embase and Cochrane Library) to collect the case-control studies on the risk factors of pulmonary aspergillosis in COPD from June 1, 2000 to June 1, 2019.According to the Newcastle-Ottawa scale(NOS) developed by Wells and etc, the quality of the documents was assessed. Then meta-analysis was performed with Revman 5.3 and stata15 software.Results A total of 25 articles were included, all of which were case-control studies, including 8 in English and 17 in Chinese, with 995 cases in the case group and 3117 cases in the control group. Meta analysis showed: smoking history, length of hospital stay, stay in ICU, mechanical ventilation, invasive procedures, use of glucocorticoids, use of antibiotics, GOLD Ⅲ~Ⅳ, diabetes, fungal colonization or previous infection, hypoproteinemia, high APACH Ⅱ score it is a risk factor for pulmonary aspergillosis in patients with chronic obstructive pulmonary disease.Conclusion The occurrence of pulmonary aspergillosis in patients with chronic obstructive pulmonary disease is a result of a combination of multiple risk factors, which is closely related to the patient’s treatment, past medical history, and comorbidities. However, due to the limitations of objective factors, some results may still be biased need further research and verification.

参考文献/References:

[1]Guines J,Torres-Narbona M,Gijon P,et al.Pulmonary aspergillosis in patients with chronic obstructive pulmonary diseases:incidence,risk factors,and outcome[J].Clin Microbiol Infect,2010,16(7):870-877.[2]Kousha M,Tadi R,Soubani AO.Pulmonary aspergillosis:a clinical review[J].Eur Respir Rev,2011,20(121):156-174.[3]Segal BH,Walsh TJ.Current approaches to diagnosis and treatment of invasive a spergillosis[J].AM J Respir Crit Cars Med,2006,173(7):707-717.[4]Muquim A,Dial S,Menzies D.Invasive aspergillosis in patients with chronic obstructive pulmonary diseases[J].Can Respir J,2005,12(4):199-204.[5]陈瑞英,孙培宗,靳建军,等.慢性阻塞性肺疾病患者发生侵袭性肺曲霉病的危险因素分析[J].中国实用医药,2008,3(18):53-55.[6]罗莉,文富强.慢性阻塞性肺疾病患者并发侵袭性肺曲霉病的影响因素研究[J].四川大学学报(医学版),2010,41(4):720-722.[7]金锋.COPD继发曲霉菌感染危险因素分析[J].临床肺科杂志,2011,16(11):1705-1706.[8]李玉芝,王从政,刘美云.慢性阻塞性肺病患者侵袭性肺曲霉菌病危险因素分析[J].山东医药,2011,51(47):93-94.[9]He H,Ding L,Li F,et al.Clinical features of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases:a prospective study[J].Crit Care,2011,15(1):R5.[10]He HY,Chang S,Ding L,et al.Significance of Aspergillus spp. isolation from lower respiratory tract samples for the diagnosis and prognosis of invasive pulmonary aspergillosis in chronic obstructive pulmonary disease[J].Chin Med J (Engl),2012,125(17):2973-2978.[11]宋宁,史金英,李艳肖,等.慢性阻塞性肺病急性加重期合并侵袭性肺曲霉菌病的危险因素分析[J].河北医药,2012,34(1):87-88.[12]Xu H,Li L,Huang WJ,et al.Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease:a case control study from China[J].Clin Microbiol Infect,2012,18(4):403-408.[13]段秋立,门琤,冯冬冬.慢性阻塞性肺病合并肺曲霉病的治疗及影响因素分析[J].中国医学工程,2013,21(11):142-143.[14]刘亚,黄相增.COPD病人并发IPA危险因素分析[D].新疆医科大学,2013.[15]赵磊,毕丽鑫,王辉.慢性阻塞性肺病合并肺曲霉病的治疗及影响因素分析[J].临床合理用药,2013,6(40):84-85.[16]Delsuc C,Cottereau A,Frealle E,et al.Putative invasive pulmonary aspergillosis in critically ill patients with chronic obstructive pulmonary disease:a matched cohort study[J].Crit Care,2015(19):421.[17]刘红丹,贺航咏,孙兵,等.重症慢性阻塞性肺疾病合并侵袭性支气管-肺曲霉菌病的临床特点:巢式病例对照研究[J].国际呼吸杂志,2015(9):676-680.[18]臧宁,徐爱珍,温明春,等.慢性阻塞性肺疾病急性加重期痰曲霉菌阳性患者临床特征及危险因素分析[J].国际呼吸杂志,2015,35(11):823-826.[19]丁宗励,陈建辉.运用多元Cox回归模型分析影响慢性阻塞性肺疾病合并侵袭性肺曲霉菌病的危险因素[J].中国医刊,2016,51(11):79-81.[20]陆薇,梁克诚,卢翠梅,等.COPD合并侵袭性肺曲霉菌病的危险因素及临床特点分析[J].中国临床研究,2016,29(7):892-895.[21]汪群智,盛美玲,楼亚波.慢性阻塞性肺疾病合并侵袭性肺曲霉病的危险因素及临床特征分析[J].中华临床感染病杂志,2016,9(6):528-532.[22]杨仁恒.慢性阻塞性肺疾病并侵袭性肺曲霉菌病患者的临床表现及胸部CT表现分析[J].实用心脑肺血管杂志,2016,24(1):105-107.[23]杜俊凤,任少达,迟玉敏,等.慢性阻塞性肺疾病并发侵袭性肺曲霉菌病的临床特征和危险因素分析[J].中国医学前沿杂志,2017,9(7):132-135.[24]毛文炜,顾海挺,邵海燕,等.慢性阻塞性肺病急性加重期患者合并侵袭性肺曲霉菌感染的危险因素分析与临床[J].中华医院感染学杂志,2017,27(15):3442-3445.[25]宋小峰.慢性阻塞性肺病曲霉菌痰培养阳性的多因素分析[D].青岛大学,2017.[26]Tong X,Cheng A,Xu H,et al.Aspergillus fumigatus during COPD exacerbation:a pair-matched retrospective study[J].BMC Pulm Med,2018,18(1):55.[27]Molinos-Castro S,Pesqueira-Fontán PM,Rodríguez-Fernández S,et al.Clinical factors associated with pulmonary aspergillosis in patients with chronic obstructive pulmonary disease[J].Enferm Infecc Microbiol Clin,2020,38(1):4-10.[28]Ader F,Nseir S,Le Berre R,et al.Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease:an emerging fungal pathogen[J].Clin Microbiol Infect,2005,11(6):427-429.[29]Bulpa PA,Dive AM,Garrino MG,et al.Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis:benefits of intensive care[J].Intensive Care Med,2001,27(1):59-67.[30]Barberán J,Candel FJ,Arribi A.How should we approach Aspergillus in lung secretions of patients with COPD[J].Rev Esp Quimioter,2016;29(4):175-182.[31]Bao Z,Chen H,Zhou M,et al.Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease:a case report and review of the literature[J].Oncotarget,2017,8(23):38069-38074.[32]Venanzi-Rullo E,Fortun-Abete J,Nunnari G.Diagnosing invasive pulmonary aspergillosis in COPD patients: more challenging and less rare than before.A review of the literature[J].Infect Dis Trop Med,2016,2(4):E341.[33]Dutkiiewick R,Hage A.Aspergillus infection in the critically ill[J].Proc Am Thor Soc,2010,7(3):204-209. [34]张莉芸,李军霞,王婷艳.糖皮质激素对Th1/Th2平衡的影响[J].中华临床免疫和变态反应杂志,2009(1):64-68.[35]胡艳艳.慢性阻塞性肺疾病与肺曲霉菌感染的研究进展[J].中华肺部疾病杂志(电子版),2014,7(2):88-91.[36]Liang S,Jiang R,Lu HW,et al.Immunity status of invasive pulmonary aspergillosis patients with structural lung diseases in Chinese adults[J].Thorac Dis,2017,9(2):247-253.[37]Barberán J,García-Pérez FJ,Villena V,et al.Development of Aspergillosis in a cohort of non-neutropenic,non-transplant patients colonised by Aspergillus spp[J].BMC Infect Dis,2017,17(1):34.[38]Wu Y,Xu H,Li L,et al.Susceptibility to Aspergillus Infections in Rats with Chronic Obstructive Pulmonary Disease via Deficiency Function of Alveolar Macrophages and Impaired Activation of TLR2[J].Inflammation,2016,39(4):1310-1318.

更新日期/Last Update: 1900-01-01